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ABSTRACT
Microbial contamination of hematopoietic stem cell products is a rare but potentially fatal complication of
hematopoietic stem cell transplantation. We report the incidence of contaminated products and describe the
clinical outcomes for 35 patients at the University of Minnesota who received contaminated products from
January 1990 to December 2004. In total, 2935 products were infused for 2863 transplants during this time, 36
of which 36 (1.2%) were contaminated. Coagulase negative Staphylococcus was the predominant species isolated
on culture of the hematopoietic stem cell products. Patients received prophylactic antibiotics before infusion
of the contaminated product based on the organism identified from culture and antibiotic sensitivities, if
known. After transplantation, blood cultures from 2 patients grew the same pathogen as in the infused
contaminated product, including 1 patient who had blood cultures positive for Pseudomonas cepacia. All patients
who received contaminated products had benign post-transplantation courses except for the patient with
Pseudomonas bacteremia, who ultimately died from complications. These results suggest that, although rare,
microbial contamination of stem cell products does occur and there must be ongoing efforts by physicians and
laboratory personnel to minimize the risk for introduction of contaminants. Prophylactic antibiotics are useful
for certain contaminants; however, caution must be exercised when gram-negative contaminated products are
administered.
© 2006 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Intravenous infusion of microbially contaminated
ematopoietic stem cell (HSC) products is a potential
ource of morbidity and mortality in immunocompro-
ised transplant recipients. Possible sources of con-
amination include asymptomatic bacteremia of the
atient or donor at time of collection, infected cath-
ters or skin plugs from venous access, and improper
xecution of aseptic technique during collection or
rocessing.
Standard practice is to harvest bone marrow (BM)
nder sterile conditions in operating rooms, periph-
ral blood stem cells (PBSCs) via apheresis, and um-
ilical cord blood (UCB) after birth in hospital obstetric
nits. The potential for and mechanism of contamina-
ion differ for these various collection methods. Once
ell products are collected, they are transferred to the c
142ell-processing laboratory, where they may undergo fur-
her manipulation ranging from minimal ex vivo pro-
essing to more extensive cell-engineering techniques.
s cell engineering becomes more complex, the po-
ential for introducing a contaminant through labora-
ory processing is increased.
Contamination rates for stem cell products have
een reported as 0%-45% [1-19]. Although some con-
aminated products described in published reports
ere discarded, most products were transfused by
hoice or necessity. In 4 reports, subsequent blood
ultures yielded the same organisms as in the contam-
nated graft [12,15,19,20]. However, no signiﬁcant
dverse clinical outcomes or deaths resulted.
Such a wide range of reported contamination rates
uggests institutional differences in harvesting, pro-
essing, and thawing protocols and an improvement in
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Microbial Contamination of HSC Products 1143ollection systems and processing techniques over
ime. We report the University of Minnesota experi-
nce with HSC product (BM, PBSCs, and UCB) con-
amination, including incidence, likely etiologies, and
linical sequelae of infusion.
ETHODS
atients
Between January 1990 and December 2004, 2863
onsecutive patients with various malignant and non-
alignant hematologic disorders underwent trans-
lantation at the University of Minnesota. In total,
935 HSC products were infused because some pa-
ients received 2 products (BM plus PBSC). All pa-
ients received prophylactic antimicrobials directed
oward bacterial, fungal, and viral pathogens begin-
ing 1 day before transplantation. The Cell Therapy
aboratory processing records for these patients were
xamined for results of sterility testing. Medical
ecords of those patients identiﬁed as having received
ontaminated stem cell products were then reviewed
n detail. Data gathered included whether the product
as known to be contaminated, prophylactic antibi-
tic administration, and clinical sequelae that oc-
urred from time of infusion to 14 days after trans-
lantation, including side effects of infusion, results of
lood cultures and antibiotic sensitivities, and devel-
pment of end-organ toxicity. The study protocol was
pproved by the institutional review board.
terility Testing
Before 1998 all stem cell products were sampled
or bacterial and fungal cultures immediately after
ollection/before processing and again immediately
fter processing. Subsequently, due to the low inci-
ence of contaminated products, a policy change was
ade to discontinue routine sampling after collection
nd to obtain cultures for sterility testing only at the
ompletion of processing before cryopreservation of
SC products and before the release of fresh products
allogeneic PBSC and BM) or thawed UCB from the
aboratory for infusion. Sterility testing was not typi-
ally repeated after thawing of cryopreserved products
nless tears were found in the product bag or breakage
ccurred during thawing.
tem Cell Collection
Stem cells were collected by BM harvest, aphere-
is, or cord blood drainage. BM was harvested from
he posterior iliac crest under general anesthesia in the
perating room using sterile techniques. Through a
eries of aspirates, BM was collected in sterile syringes
ontaining heparin and electrolyte solution (Plasma-
yte A [Baxter Healthcare Corporation, Deerﬁeld,
L] or Minimum Essential Media [Invitrogen, Grandsland, NY]). The contents of the syringe were trans-
erred to a sterile disposable bag ﬁltration system in
hich the marrow passed through a series of inline
lters of decreasing size for removal of particulate
atter to a ﬁnal product bag.
PBSCs were collected by apheresis from autolo-
ous and allogeneic donors using a Baxter Fenwal
S3000 Plus Blood Cell Separator (Baxter Healthcare
orporation, Deerﬁeld, IL) [21]. Blood was removed
rom the donor through a central venous catheter port
r a peripheral venipuncture site and mixed with an-
icoagulant solution as it entered the instrument. The
otal blood volume processed ranged from 15 L for
dults to 3-6 blood volumes for pediatric donors.
he volume of the ﬁnal product was approximately
0-80 mL.
UCB collections for related donations were often
erformed in the early years of our study by inexpe-
ienced obstetrics staff using an open system in which
he cord was transected and blood allowed to drain
nto a sterile container containing anticoagulant (ci-
rate phosphate dextrose, Baxter Fenwal) and antibi-
tics. Collections for unrelated donations were per-
ormed by various UCB banks using primarily closed
ystems (blood bag sets). Unrelated donations were
ore prominent in the later years of our study group.
CB collection volumes by either method typically
anged from 50 to 150 mL.
rocessing Techniques
Most (93%) products underwent minimal cell ma-
ipulation in the laboratory, which involved removal
f unwanted red blood cells and plasma, volume re-
uction, stem cell selection, or cryopreservation be-
ore infusion. Of the 7% of products involved in
xtensive cell processing, techniques included coun-
erﬂow centrifugal elutriation, cell expansion, gene
odiﬁcation, and tumor cell purging. A brief descrip-
ion of stem cell processing techniques used during
he period of study follows.
Minimal Manipulation Cell Processing
PBSC and UCB. Collections were weighed and
sampled for total nucleated cell count, cell differ-
ential, CD34 cell and colony-forming unit, and
viability. All manipulations were performed in a
biological safety cabinet. For most allogeneic
PBSC products, no further processing was neces-
sary. Autologous PBSC and UCB cells were cryo-
preserved and stored in liquid nitrogen (LN2)
storage tanks until the day of infusion.
Autologous BM buffy coat preparation. Process-
ing was performed with a COBE 2991 Cell Pro-
cessor. BM was transferred to a sterile disposable
tubing set (Baxter Healthcare Corporation, Deer-
ﬁeld, IL) connected to the device. Cells were
centrifuged at 1240g until visible layers of plasma,
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M. A. Klein et al.1144red blood cells, and buffy coat (white blood cells)
were created. The buffy coat layer was extracted
into a sterile plastic bag and cryopreserved.
Allogeneic BM. Laboratory manipulation in-
cluded centrifugation for removal of plasma for
minor ABO incompatibilities and volume reduc-
tion, red blood cell depletion by hydroxyethyl
starch sedimentation technique for major ABO
incompatibility, and CD34 selection with an im-
munomagnetic cell selection device (Isolex 300i
Magnetic Cell Separation System [Baxter Health-
care Corporation, Deerﬁeld, IL]).
Extensive Manipulation Cell Processing. Techniques
ncluded T cell depletion by counterﬂow centrifugal
lutriation, transduction of retroviral vector, and tu-
or purging with pharmacologic agents (interferon-,
icin, and 4-hydroperoxycyclophosphamide). Tech-
iques involved multiple transfers of cells via bags,
ubes, and/or syringes. Many of these processes in-
olved extensive incubation and exposure to reagents
ot approved for human use and not manufactured
nder standards currently mandated by the Food and
rug Administration (FDA).
ryopreservation
Stem cell products were cryopreserved using a
ryoprotectant solution consisting of dimethylsulfox-
de, electrolyte solution (Plasma-Lyte A), and 20%
uman serum albumin or autologous serum. Products
ere aseptically transferred to sterile cryogenic bags
hrough syringes and combined with an equal volume
f cryoprotectant solution. The product was placed in
controlled-rate freezer and frozen to100°C. Prod-
cts were then transferred to LN2 storage containers
n direct contact with LN2 (products frozen from 1990
o 1996) or in vapor phase at 135°C (products
rozen from 1997 to 2004).
nfusion of Stem Cell Products
All stem cell products were infused on the patient
are unit. Cryopreserved products were transported to
able 1. Microbially Contaminated Stem Cell Products
HSC Product Preprocessing* Postprocessing*
M 13 9
Allogeneic 10 5
Autologous 3 4
BSC 4 2
Allogeneic 1 0
Autologous 3 2
CB 3 4
Related 3 2
Unrelated 0 2
otal 20 15
SC indicates hematopoietic stem cell; BM, bone marrow; PBSC,
Phase in processing when contamination occurred.
Total number of the type of product infused at our center during studyhe patient care unit in a LN2 portable shipping con-
ainer, placed in sterile overwrap plastic bags, and gently
hawed in a water bath containing sterile saline. Once
hawed the cells were directly injected into the patient’s
ntravenous access or hung and administered by con-
rolled drip. Frozen UCB products were thawed in the
aboratory on the day of transplantation, washed with a
0% dextran 40/5% human serum albumin solution,
nd transported to the patient care unit for timely infu-
ion.
ag Breakage Protocols
The Cell Therapy Laboratory followed established
rocedures in the event that a break occurred at the time
f thaw. If a minor break occurred, the hole or tear was
ealed with a sterile hemostat and thawing was contin-
ed. If a major break occurred, the stem cell product was
ollected in a syringe as it thawed and transferred into a
terile bag. Samples for culture were obtained from all
ags that leaked or broke. The transfusion medicine and
ransplantation attending physicians were notiﬁed by the
ell Therapy Laboratory medical director, and clinical
ecisions regarding appropriate management, including
se of broad-spectrum antibiotics, were made.
ESULTS
atient Characteristics
Thirty-ﬁve patients (21 men, 14 women), with a
edian age of 25 years (range, 7 months to 61 years),
eceived 36 contaminated stem cell products (1 patient
eceived a second transplant due to failure of the ﬁrst
SC product to engraft; each graft was contaminated
ith coagulase-negative Staphylococcus [CNS]). The
ypes of diseases necessitating transplantation in-
luded acute and chronic myelogenous leukemias,
ymphoma, and BM failure syndromes.
ontaminated HSC Products
Thirty-six (1.2%) of the 2935 HSC products were
ontaminated with microorganisms. The stem cell
haw* Total
Total HSC
Products†
Incidence of
Contamination (%)
1 22 1666 1.3
0 15 1257 1.2
1 8 409 2.0
0 6 919 0.7
0 1 296 0.3
0 5 623 0.8
0 7 350 2.0
0 5 18 27.8
0 2 332 0.6
1 36 2935 1.2
eral blood stem cell; UCB, umbilical cord blood.At T
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Microbial Contamination of HSC Products 1145ources of contaminated products are listed in Table 1.
M accounted for 22 (61%) of the 36 contaminated
roducts. Of the 3 types of HSC products, UCB had the
ighest incidence of contamination at 2.0%.
The phase when contamination occurred was iden-
iﬁed upon review of processing records (Table 1).
wenty (55%) products had contamination identiﬁed
efore processing, 15 (42%) after processing, and 1 (3%)
as identiﬁed after a bag break of autologous BM at
he time of thaw. Of the 20 contaminated products
dentiﬁed before processing, 13 were BM, 4 were
BSCs, and 3 were UCB. Of the 15 products contam-
nated as a result of product processing, 9 were BM, 2
ere PBSCs, and 4 were UCB; 9 products were min-
mally manipulated and 6 were extensively manipu-
ated during processing.
Six patients received contaminated autologous
BSC. Of these 6 patients, 5 had collection through a
entral venous catheter and 1 through antecubital
eins. Two of the patients with central venous cathe-
ers had CNS bacteremia during the time of apheresis;
of these products was found to be microbially con-
aminated with CNS before processing and 1 was
ontaminated after processing.
icrobial Organisms
Seventeen different bacterial or fungal organisms
ere found to be contaminants (Table 2). CNS was
he most common isolate and was found in 19 HSC
roducts. Bacillus was the next most frequent, being
ound in 4 products. Gram-negative organisms and
old/fungi were uncommon.
linical Outcomes
Of the 35 patients who received contaminated
roducts, 34 had benign clinical courses. Antibiotics
able 2. Contaminating Organisms and Stem Cell Products
Organism
oagulase-negative Staphylococcus
acillus sp
acillus cereus
erococcus sp
-Hemolytic streptococcus
spergillus fumigata
acteroides vulgatus
ifidobacterium sp
andida parasilopsis
lostridium sp, not perfringens
orynebacterium sp
scherichia coli
ram-positive cocci in clusters, not otherwise specified
lebsiella pneumonia
on-group D enterococcus sp
eptostreptococcus sp
seudomonas cepacia
otal
SC indicates hematopoietic stem cell; BM, bone marrow; PBSC,
More than 1 organism contaminated 3 products.ere changed in response to information received
bout the contaminated product for 16 patients; for
he remaining 19 patients, the prescribed antibiotics
ere deemed appropriate or not commented on in the
edical record. One patient was infused with Klebsiella
neumonia and Escherichia coli from a related UCB.
his was known at infusion, and the patient was begun
n ceftazidime and trimethoprim/sulfa based on anti-
iotic sensitivity results. This patient had only 2 fe-
rile episodes (days 6 and 8 after infusion) with no
erious clinical sequelae and no positive blood cultures
n the ﬁrst 14 days after infusion.
Nine of the 35 patients subsequently developed
ositive blood (n  8) or bile (n  1) cultures within
4 days after transplantation (Table 3). Blood culture
solates were identical to the infused species in 2 pa-
ients, different in 6 patients, and unknown (antibiotic
ensitivity results unknown) in 1 patient. At the time
f stem cell infusion, all patients were on prophylactic
ntibiotics or being treated for an already isolated
icroorganism. Antibiotics were added or changed in
patients due to reporting of the positive stem cell
roduct, documentation was unclear in 2 patients, and
patients had no modiﬁcation in antibiotics. Of the
HSC products, 3 were identiﬁed as being contami-
ated before processing and 6 after processing. Of
hese 6 postprocessing events, 4 products underwent
inimal and 2 extensive processing. Of the 4 products
hat underwent minimal processing, 3 were cryopre-
erved products (1 autologous PBSC, 1 related UCB,
nd 1 unrelated UCB) and 1 was an unrelated BM that
as not manipulated. The unrelated UCB also under-
ent washing. Of the 2 extensively manipulated prod-
cts, both were autologous BM products that under-
ent incubation with interferon-. One product was
lso subject to a buffy coat preparation. The other
aminated Products (n)* HSC Product (n)
19 BM (12), PBSC (5), UCB (2)
3 BM (2), PBSC (1)
1 BM
1 PBSC
1 BM
1 BM
1 UCB
1 UCB
1 BM
1 UCB
2 BM (2)
1 UCB
1 BM
1 UCB
1 UCB
1 UCB
1 BM
38
eral blood stem cell; UCB, umbilical cord blood.Cont
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M. A. Klein et al.1146roduct had a mononuclear cell preparation centrifu-
ation step; the patient who received this product is
escribed below.
One patient who underwent a myeloablative au-
ologous BM transplantation in 1991 died of compli-
ations from sepsis. At the time of BM harvest, the
atient was clinically well and cultures obtained after
ollection/before processing were negative. The BM
roduct was extensively manipulated and purged with
nterferon-, a process that included 8 steps, many
n open systems. Pseudomonas cepacia was isolated from
he BM product after processing and from blood cul-
ures obtained from the patient after transplantation
Table 4). When culture results of the HSC product
ecame known, the patient had already received pre-
ransplantation conditioning and no other source of
SC was available. Based on antibiotic sensitivity test-
ng, the patient was placed on trimethoprim/sulfame-
hoxazole and piperacillin 3 days before infusion.
cetaminophen, lorazepam, and hydrocortisone were
able 3. Summary of Patients with Post-transplantation Positive Blood
Stem Cell Source
Phase Contamination
Occurred/Degree of
Manipulation Stem Cell Isolate
utologous PBSC Postprocessing/minimal CNS
nrelated BM Postprocessing/minimal CNS
utologous BM Postprocessing/extensive Pseudomonas cepac
nrelated BM Preprocessing CNS
utologous BM Postprocessing/extensive Corynebacterium sp
nrelated UCB Postprocessing/minimal CNS
utologous PBSC Preprocessing CNS
elated UCB Postprocessing/minimal CNS
llogeneic PBSC Preprocessing Aerococcus sp
NS indicates coagulase-negative Staphylococcus; BM, bone marr
VRE, vancomycin resistant enterococcus.
able 4. Sensitivities of Pseudomonas cepacia by Site
Antibiotic Bone Marrow Blood
mikacin R R
efoperazone R R
efotaxime I R
hloramphenicol R I
entamicin R R
ezlocillin R R
iperacillin S S
etracycline R R
icarcillin R R
obramycin R R
rimethoprim/sulfamethoxazole S Stindicates intermediate; R, resistant; S, sensitive.dministered before infusion of the product. During
nfusion the patient became unresponsive, hypoten-
ive, and bradycardic. After the patient was resusci-
ated with intravenous ﬂuids, 3 more doses of hydro-
ortisone were administered in conjunction with
iphenhydramine, and the remaining product was in-
used uneventfully.
Later on the day of transplantation, the patient
ecame febrile, tachypneic, complained of chest pain,
nd had a decline in urine output. By the next day,
asopressors were required to maintain an adequate
lood pressure, and right atrial catheter readings
ere consistent with septic shock. Disseminated in-
ravascular coagulation, renal failure, and respira-
ory failure ensued. Pseudomonas cepacia grew from
atient blood cultures obtained on post-transplan-
ation days 2 and 3 that had the same antimicrobial
ensitivities as the HSC product isolate (Table 4).
he patient died on post-transplantation day 7 from
ultiorgan failure.
ISCUSSION
We report the type and incidence of microbial
ontamination, phase of processing during which con-
amination occurred, and the clinical sequelae of in-
using contaminated stem cell products at a single
nstitution over the course of 14 years. In total, 2935
SC products, including 350 UCB, were infused dur-
ng the study period, with an overall 1.2% incidence of
ontamination. The organisms isolated in the stem
ell products were predominantly skin-colonizing or-
anisms and water-borne organisms, which is consis-
es
Blood Culture
Isolate Strain
Change in Antibiotics in
Response to Contaminated
Stem Cells
S Same Vancomycin added
S Unknown None—already on vancomycin
udomonas cepacia Same Trimethoprim/sulfamethoxazole
added
ndida tropicalis Different None—already on vancomycin
udomonas
eruginosa
Different Unknown
ndida krusei Different Changed from cefazolin to
vancomycin
S in bile Different Vancomycin added
E and group D
nterococcus
Different Unknown
CNS Different Vancomycin added
-Hemolytic
treptococcus
Moraxella sp
Proteus mirabilis
BSC, peripheral blood stem cells; UCB, umbilical cord blood;Cultur
CN
CN
ia Pse
Ca
Pse
a
Ca
CN
VR
e
1.
2.
s
3.
4.
ow; Pent with previous reports [1-19].
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Microbial Contamination of HSC Products 1147The reported incidence of stem cell contamina-
ion rates is 0%-45% [1-19]. This wide range is likely
nﬂuenced by multiple factors, including stem cell
ource, collection technique, extent of product manip-
lation, and center size. Over time, the source of stem
ells has changed, with BM being the predominant
SC source in the early 1980s. BM is collected in the
perating room under sterile conditions; however, the
ollection system in the 1980s consisted of multiple
pen containers. Ultimately, a closed system with an
nline series of ﬁlters was developed. By the late 1980s
nd early 1990s, PBSCs emerged and have remained a
rimary HSC source. Central venous catheters, al-
hough convenient for apheresis, have a propensity to
ecome infected in neutropenic, immunocompromised
atients and are a source of PBSC product contamina-
ion. Most recently, UCB has emerged as a source of
tem cells. The ﬁrst UCB transplants were performed
rom related donors at a time when, now antiquated,
pen-system collection techniques were employed; col-
ectors had little training, and if the product was micro-
ially contaminated, it was typically used by necessity.
urrently, UCB stem cells are collected with a closed-
ystem technique and, in the case of public UCB banks,
hose products that are microbially contaminated are not
ypically entered into usable inventory.
A thorough review of the laboratory procedural
ecords of the contaminated products was conducted
or this study in an effort to identify the sources of
ontamination. About 50% of the products were con-
aminated before receipt into the laboratory. These
M and PBSC products were most likely contami-
ated during collection due to inadequate aseptic
echnique of the skin before puncture, because skin
ontaminants comprised most of the organisms iden-
iﬁed from these products. After collection, even min-
mal manipulation resulted in contamination; how-
ver, the degree of product manipulation was likely a
ritical factor in the rate of stem cell contamination.
lthough all transfers of cells were performed in bio-
ogical safety cabinets using sterile disposable syringes,
ubing, and bags, the potential remained for introduc-
ng contamination at each processing step by failure to
se proper aseptic techniques. Our patient who suc-
umbed to complications from sepsis received an au-
ologous BM that had undergone extensive manipula-
ion that included 8 steps, many of which were in
pen systems. Although the small number of contam-
nated products in our study precludes a formal anal-
sis of any correlation between contamination rates
nd degree of product manipulation, we recommend
hat physicians caring for patients who receive prod-
cts that undergo multiple manipulations have a
eightened awareness of the possibility of infusion of
ontaminated products.
Skin, reagents, processing steps, and equipment
uch as water baths, incubators, and centrifuges have peen shown to be potential sources of contamination
1-19]. Hirji et al [17] described an outbreak in stem
ell products in which Actinomycete was isolated; a
hange in protocol signiﬁcantly decreased contamina-
ion rates. In that report, examination of the collec-
ion, processing, and administration process yielded
o breaks in the infection-control technique at rein-
usion, and cultures of the equipment, staff hands,
otted plants, water bath, and LN2 tanks did not yield
he outbreak isolate. Eventually, evaluation of the
ryopreservation process revealed multiple potential
ources of contamination, including using a multiple-
se bottle for cryopreservation media, cleaning of
aminar ﬂow hoods only at the end of the day, block-
ge of the laminar ﬂow hood air ﬁlter, and using a
terile syringe to gain entry to media bottles multiple
imes instead of using sterile pipettes only once. Mul-
iple changes in processing were implemented, and
ubsequently, no additional contamination of products
ith the outbreak strain occurred.
During the period of review for this study, cell-
rocessing laboratories have witnessed the evolution
nd integration of regulations and standards by the
DA and professional organizations such as the Amer-
can Association of Blood Banks and the Foundation
or the Accreditation of Cellular Therapy. The FDA
nly recently (May 2005) introduced its ﬁrst regula-
ions for somatic cell and tissue products, known as
urrent good tissue practices [22]. These regulations
nd those of the American Association of Blood
anks and the Foundation for the Accreditation of
ellular Therapy primarily focus on patient and
roduct safety and mandate that laboratories and
ollection facilities operate under clean and sanitary
onditions and demonstrate a level of environmen-
al control that minimizes the risk for the introduc-
ion of contaminants.
Approximately equal numbers of patients in our
tudy had contamination detected before and after
rocessing. However, the change in sterility testing
rotocol implemented during the study period may
ave skewed these results by erroneously suggesting a
igher rate of contamination due to processing. It is
lso possible that contamination occurring from the
ime of collection evaded postcollection detection and
as isolated only after processing.
Expertise of donor center and laboratory person-
el may also vary among collection centers and affect
ontamination rates. Previous studies have reported a
otal number of 100 to 2000 stem cell products
rocessed by individual centers [1-19]. It is conceiv-
ble that personnel at larger centers have more train-
ng and expertise, with a resultant decreased possibil-
ty of contamination of products during collection and
rocessing.
Four previous studies have reported patients with
ost-transplantation blood cultures positive for the
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M. A. Klein et al.1148ame strain as the infused product [12,15,19,20]. In
hose reports, CNS and P cepacia were isolated. How-
ver, no signiﬁcant clinical sequelae resulted. Webb
t al [12] reported that 2 of 73 patients developed fever
nd positive blood cultures. One patient had P cepacia
solated from the infused product at 48 hours after
nfusion and in subsequent blood cultures at 72 hours
fter infusion. The isolates had identical antibiotic
ensitivities. The second patient had Staphylococcus epi-
ermidis isolated from the infusion product and blood
ultures. In an analysis by Schwella et al [15] of 38
atients who received contaminated autologous BM ,
had BM and subsequent post-transplantation iso-
ates grew CNS. Larrea et al [19] reported on 28
atients who received contaminated products. Nine of
9 patients developing fever after transplantation had
ositive blood cultures; 3 patients were bacteremic
ith a CNS isolate identical to that of the infused
ontaminant. A case report by Nifong et al [20] was of
patient who received an autologous PBSC transplant
ontaminated with CNS. The patient had an identical
rganism isolated on blood cultures after product in-
usion. The patient had been on prophylactic antibi-
tics and no serious clinical sequelae ensued.
We describe the only other reported case of a
roduct contaminated with P cepacia resulting in post-
ransplantation positive patient blood cultures with
he same strain of organism. Although the patient
eveloped side effects from the infusion itself, these
ay have been due, at least in part, to the lack of
iphenhydramine as part of the prescribed premedi-
ations. Despite initiation of appropriate antibiotics
efore infusion of the product, the patient ultimately
ied. This is the only reported death presumed due to
n infused contaminated stem cell product. The phase
f processing when contamination occurred was most
ikely during processing, because cultures obtained
fter collection/before processing were negative.
Although the incidence of contaminated HSC
roducts is low, steps to prevent contamination should
ontinue to be employed at all times. To prevent
ontamination by skin organisms during the collection
f PBSC with central catheters or peripheral lines, a
echnique of diversion and disposal of the ﬁrst few
illiliters to eliminate the skin-plug phenomenon has
een suggested [23]. When possible, only closed col-
ection systems should be used, the number of manip-
lation steps should be kept to an absolute minimum,
nd personnel should undergo routine training in the
septic techniques of collection and processing of
SC products.
Serious clinical sequelae from contaminated stem
ell products are rare. Skin ﬂora contaminants are
ikely to be innocuous or covered by prophylactic
ntibiotics as part of many transplantation center pro-
ocols. In contrast, we recommend that prophylactic
ntibiotics always be administered when HSC prod-cts are contaminated with gram-negative organisms
r that, if possible, an alternative HSC product be
hosen.
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